PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY
Author(s)
Casilli G1, Lidonnici D1, Isernia M1, Morichi M1, Konstanski M2, Kuchenbecker U2, Mittendorf T2, Lanati P1
1MA Provider Srl, Milano, MI, Italy, 2Xcenda GmbH, Hannover, Germany
Presentation Documents
OBJECTIVES: With innovative, high-priced drugs, it becomes more relevant to timely plan the launch sequence and submission to HTA authorities, which could affect pricing strategies. Aim of this study was to analyse the impact of price negotiations and compare outcomes of process in Italy vs. Germany. METHODS: Price information of 82 new medicinal products (January 2015 to June 2019) were available for Italy and Germany. Analyses were conducted according to their orphan status, therapeutic area, innovative status and reimbursement class (based on Italian criteria). For Italy/Germany, published ex-factory prices at date of launch (Official Gazettes/Lauertaxe, including mandatory temporary reductions) were compared with net prices including confidential discounts after price negotiation (tracked by regional public tenders/Lauertaxe). Finally, we made a comparison of the ex-factory and net/reimbursed prices between countries. RESULTS: Compared to Germany, the Italian ex-factory price was on average 22% lower. Subgroup analysis showed that Italian vs German ex-factory price was -27% for orphan drugs (n=25), -15% for innovative drugs (n=23), -20% for oncological drugs (n=27) and -26% for uncategorised drugs (n=32). Analysing prices after negotiation processes, Italian net price resulted on average 23% lower than German reimbursed price. Subgroup comparison (Italian vs. German net/reimbursed price) showed -21% for orphan drugs (n=25), -24% for innovative drugs (n=23), -19% for oncological drugs (n=27) and -24% for uncategorised drugs (n=32). Price negotiation yielded to additional price reduction of 25% on average in Germany and 24% in Italy. Italian reimbursement before G-BA assessment (n=14) resulted in net prices on average 55% lower than German launch price. CONCLUSIONS: Our analysis highlighted that negotiated discounts in Italy are higher than in Germany leading to lower prices of drugs. Companies should carefully plan their launch sequence and design accurate access scenarios, being difficult to reset the price afterwards.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PMU65
Topic
Health Policy & Regulatory
Topic Subcategory
Insurance Systems & National Health Care, Pricing Policy & Schemes, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
Multiple Diseases